Analysts: EMA Less Severe on Ariad’s Iclusig Than the FDA and 3 More Research Notes to Read

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Citigroup says the European Medicines Agency’s initial change on the use of Ariad’s leukemia drug Iclusig was less severe than the U.S. Food and Drug Administration’s; Citi says the news was in line with its expectations and that it expects any volatility in shares on Friday to “normalize relatively quickly.” Citi has a Neutral rating on shares of Ariad.

Johnson Controls Inc. (NYSE:JCI): R.W. Baird said Johnson Controls is its Top Idea, as it believes the company will leverage its invested capital with its Building Efficiency backlog; the firm also noted the company’s increased share buyback, raised dividend, and acquisitions as reasons to maintain its Outperform rating and $56 price target on Johnson Controls.